In 2013, the main causes of death in France was cancer. That year 163,602 French individuals died of cancer, regardless of gender. Diseases appear to be the leading causes of death in Europe and Western countries. Ischaemic heart diseases, as well as other circulatory system diseases kill millions of Europeans every year.

Diseases are the leading causes of death in France and worldwide

In 2018, there were more than 601,000 deaths in France. Most of them were caused by cancer and other diseases. Tumor is the leading cause of death among French men, while women seem more affected by heart diseases. In Europe in 2016, the cause of death with the greatest likelihood of death was cancer, which occurred in 265 people out of every 100,000 Europeans. Despite the development of medicine and technological progress, health issues like cancers keep being the main causes of death among the human population.

The increase of life expectancy

Even though tumors and other heart diseases are responsible for the majority of deaths in the world, it appears that medical advances in the last years and decades have a real impact on mortality rate worldwide. Between 2007 and 2017 alone, the global death rate went from 8.08 deaths per 1,000 inhabitants to 7.62. Similarly, the global child mortality rate has fallen steadily across the world since the sixties. These different factors had led to an increase of life expectancy. In 2016, the average life expectancy at birth worldwide reached 72 years, compared to 64 years in 1990.

The mortality rate has been stable in France since the middle of 1980s. The mortality rate varies between *** and ***** deaths per 1,000 inhabitants. Life expectancy of women in France amounted to more than 85 years in 2023, making the country one of the areas in Europe where women live the longest. A slowly increasing death rate From 2014 to 2020, the death rate in France generally remained stable, oscillating mostly between *** and *** deaths per 1,000 population. Death rate, also known as mortality rate, is the ratio between the annual number of deaths and the average total population over a given period and on a specific territory. In 2023, the population in France reached ***** million people, while in 2022, the total number of deaths in France was *******. The mortality rate in France increased slowly in recent years. In 2007, the death rate amounted to *** per thousand population, compared to *** deaths ten years later. Causes of death In 2013, the leading cause of death among French citizens was cancer. That year, ******* people died of tumors, while diseases of the circulatory system were the second most common cause of death in the country. Mortality rate because of cancer was particularly high among French males, whereas females appear to be more affected by cardiovascular disease. Studies have shown that cancer was not only the leading cause of death in France, but also in Europe. More broadly, health and diseases were among the major causes of death in European countries, even if traffic accidents killed more than ***** individuals in France in 2021.

This graph presents the distribution of the leading causes of death among women in France in 2017. The statistic reveals that 75.8 thousand French women died from circulatory system diseases that year.

This graph illustrates the distribution of young people and children who died in France in 2014, by age and cause of death. That year, about 60 percent of people being between 15 and 14 years old died from external causes such as accidents or suicide.

In 2022, there were 675,122 deaths in France. Of course, this figure must be related to the total population. In 2022 the death rate in France was 9.9 per 1,000 inhabitants.

Deaths in France

Despite being the second most populous country in Europe, France was ranked fourth in term of number of deaths in Europe in 2017. As in other Western countries, the leading causes of death among the French population appear to be diseases and cancer. In 2017, more than 73 thousand French women died of cancer,. Circulatory system diseases were also one of the most frequent causes of death. Regarding external causes of death, France has been fighting for years against road deaths. Prevention campaigns, as well as new traffic regulations, have led to a decrease in road deaths in France since 2006.

Aging in France

France has one of the highest life expectancies in Europe. In 2021, female life expectancy at birth reached 85.5 years, while male life expectancy amounted 79.4 years. The French appear to be concerned about health issues, now that the population of the country is getting older. However, since the mid-2000s the number of healthy life years of French male citizens at birth come over 63 years old, whereas it reaches 58 years old in Germany.

UNICEF's country profile for France, including under-five mortality rates, child health, education and sanitation data.

Immuno Oncology Diagnosis Market Outlook

The global immuno oncology diagnosis market size was valued at $2.5 billion in 2023 and is projected to reach $7.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 13.7% during the forecast period. This marketÂ’s growth is driven primarily by the rising incidence of cancer and advancements in diagnostic technologies that enable early and precise detection of oncological conditions.

One of the primary growth factors for the immuno oncology diagnosis market is the increasing prevalence of cancer globally. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with approximately 19.3 million new cases and 10 million cancer-related deaths in 2020. The rising cancer incidence necessitates advanced diagnostic solutions to ensure early detection and effective treatment, thereby driving the demand for immuno oncology diagnostics. Additionally, the growing awareness about the importance of early cancer diagnosis among the general population and healthcare providers further fuels market growth.

Another significant growth factor is the advancements in diagnostic technologies. Innovations such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), and flow cytometry have revolutionized the field of oncology diagnostics. These technologies offer enhanced accuracy, specificity, and sensitivity in detecting cancer biomarkers, thereby improving diagnostic outcomes. The integration of artificial intelligence (AI) and machine learning in diagnostic tools also holds immense potential for improving diagnostic efficiency and accuracy, further propelling market growth.

The increasing investment in cancer research and development by governments, healthcare organizations, and pharmaceutical companies is also a key driver for the market. Significant funding and grants are being allocated to cancer research initiatives to develop innovative diagnostic and treatment solutions. The collaboration between academic and research institutes, diagnostic laboratories, and biotechnology companies is fostering the development of advanced diagnostic assays, kits, and instruments, thereby contributing to market growth.

Immuno-Oncology is a rapidly evolving field that plays a crucial role in the development of innovative diagnostic and therapeutic solutions for cancer. This area focuses on harnessing the body's immune system to identify and combat cancer cells, offering a promising approach to cancer treatment. The integration of immuno-oncology in diagnostics has led to the development of advanced assays and biomarkers that enhance the precision of cancer detection and monitoring. By understanding the interactions between the immune system and cancer cells, researchers can develop targeted therapies that improve patient outcomes. The continuous advancements in immuno-oncology are expected to drive significant growth in the diagnostic market, providing new opportunities for early detection and personalized treatment strategies.

Regionally, North America holds the largest share of the immuno oncology diagnosis market, attributed to the presence of a well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and significant investment in cancer research. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the increasing prevalence of cancer, improving healthcare infrastructure, and rising awareness about early cancer diagnosis. Europe also holds a significant market share, with countries like Germany, France, and the UK leading in cancer research and diagnostics.

Product Type Analysis

The product type segment of the immuno oncology diagnosis market includes assays, kits, reagents, instruments, and software. Assays are a crucial component in the diagnosis and monitoring of cancer as they provide detailed information about the presence and progression of the disease. These assays are designed to detect specific cancer biomarkers, thus aiding in accurate diagnosis and personalized treatment planning. The increasing demand for early and precise cancer diagnosis is driving the growth of the assays segment. Furthermore, the development of advanced assays with higher sensitivity and specificity is anticipated to boost the market growth.

Kits are another essential product type in the immuno oncology diagnosis

This statistic presents the results of a survey on the perception of the French of the main causes of road mortality in 2017, by region. In Brittany and Normandy, 80 percent of respondents considered driving under the influence of alcohol or narcotics to be the main cause of fatal accidents on roads in general.

BR: Mortality Rate: Adult: Female: per 1000 Female Adults data was reported at 85.735 Ratio in 2023. This records a decrease from the previous number of 95.437 Ratio for 2022. BR: Mortality Rate: Adult: Female: per 1000 Female Adults data is updated yearly, averaging 147.254 Ratio from Dec 1960 (Median) to 2023, with 64 observations. The data reached an all-time high of 276.882 Ratio in 1960 and a record low of 82.860 Ratio in 2019. BR: Mortality Rate: Adult: Female: per 1000 Female Adults data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Brazil – Table BR.World Bank.WDI: Social: Health Statistics. Adult mortality rate, female, is the probability of dying between the ages of 15 and 60--that is, the probability of a 15-year-old female dying before reaching age 60, if subject to age-specific mortality rates of the specified year between those ages.;(1) United Nations Population Division. World Population Prospects: 2024 Revision. (2) HMD. Human Mortality Database. Max Planck Institute for Demographic Research (Germany), University of California, Berkeley (USA), and French Institute for Demographic Studies (France). Available at www.mortality.org.;Weighted average;

This dataset contains data from WHO's data portal covering the following categories:

Adolescent, Ageing, Air pollution, Assistive technology, Child, Child mortality, Cross-cutting, Dementia diagnosis, treatment and care, Environment and health, Foodborne Diseases Estimates, Global Dementia Observatory (GDO), Global Health Estimates: Life expectancy and leading causes of death and disability, Global Information System on Alcohol and Health, Global Patient Safety Observatory, Global strategy, HIV, Health financing, Health systems, Health taxes, Health workforce, Hepatitis, Immunization coverage and vaccine-preventable diseases, Malaria, Maternal and newborn, Maternal and reproductive health, Mental health, Neglected tropical diseases, Noncommunicable diseases, Nutrition, Oral Health, Priority health technologies, Resources for Substance Use Disorders, Road Safety, SDG Target 3.8 | Achieve universal health coverage (UHC), Sexually Transmitted Infections, Tobacco control, Tuberculosis, Vaccine-preventable communicable diseases, Violence prevention, Water, sanitation and hygiene (WASH), World Health Statistics.

For links to individual indicator metadata, see resource descriptions.

The French surveillance network for causes of equine mortality (Resumeq) was created in 2015 for the qualitative surveillance of equine mortality through the centralization in a national database of necropsy data and their subsequent epidemiological analysis. It was designed to identify the causes of equine mortality, monitor their evolution over time and space, and detect emerging diseases as early as possible. Resumeq is an event-based surveillance system involving various players and structures. It is organized around a steering body, a scientific and technical support committee and a coordination unit. Different tools have been developed specifically for Resumeq. These include standardized necropsy protocols, a thesaurus for the anatomopathological terms and the causes of equine death, and an interactive web application so that network contributors can display data analysis results. The four French veterinary schools, seventeen veterinary laboratories, and ten veterinary clinics already contribute to the production and centralization of standardized data. To date, the data from around 1,000 equine necropsies have been centralized. While most deaths were located in western France, the geographic coverage is gradually improving. Data analysis allows the main causes of death to be ranked and major threats identified on a local, regional or national level. Initial results demonstrate the feasibility and benefits of this national surveillance tool. Moreover, in the future, this surveillance could take an international dimension if several countries decided to jointly capitalize on their necropsy data.

In France, the mortality rate due to cardiovascular diseases was *** deaths per 100,000 population in 2022. Deaths from CVD have generally declined in France since 2000. The most common CVDs are heart attack, stroke, heart failure, arrhythmia and heart valve complications.

This dataset contains data from WHO's data portal covering the following categories:

Adolescent, Ageing, Air pollution, Assistive technology, Child, Child mortality, Cross-cutting, Dementia diagnosis, treatment and care, Environment and health, Foodborne Diseases Estimates, Global Dementia Observatory (GDO), Global Health Estimates: Life expectancy and leading causes of death and disability, Global Information System on Alcohol and Health, Global Patient Safety Observatory, Global strategy, HIV, Health financing, Health systems, Health taxes, Health workforce, Hepatitis, Immunization coverage and vaccine-preventable diseases, Malaria, Maternal and newborn, Maternal and reproductive health, Mental health, Neglected tropical diseases, Noncommunicable diseases, Nutrition, Oral Health, Priority health technologies, Resources for Substance Use Disorders, Road Safety, SDG Target 3.8 | Achieve universal health coverage (UHC), Sexually Transmitted Infections, Tobacco control, Tuberculosis, Vaccine-preventable communicable diseases, Violence prevention, Water, sanitation and hygiene (WASH), World Health Statistics.

For links to individual indicator metadata, see resource descriptions.

BackgroundCurrently, cardiovascular disease (CVD) is widely acknowledged to be the first leading cause of fatality in the world with 31% of all deaths worldwide and is predicted to remain as such in 2030. Furthermore, CVD is also a major cause of morbidity in adults worldwide. Among these diseases, the coronary artery disease (CAD) is the most common cause, accounting for over 40% of CVD deaths. Despite a decline in mortality rates, the consequences of more effective preventive and management programs, the burden of CAD remains significant. Indeed, the rise in the prevalence of modifiable risk factors due to changes in lifestyle and health behaviors has further increased the burden of this epidemic. Our objective was to evaluate the hospital burden of CAD via MI trends and Percutaneous Coronary Intervention (PCI) in the French Prospective Payment System (PPS).MethodsMI/PCI were identified in the national PPS database from 2009 to 2014 for patients aged 20 to 99, living in metropolitan France. We examined hospitalisation, readmission and mortality trends using standardised rates.ResultsOver the six-year period, we identified 678,021 patients, representing 900,121 stays of which, 215,224 had a MI and a PCI. Admission trends increased by nearly 25%. Acute MI cases increased every year, with an alarming increase in women, and more specifically in young women. Men were 3 times more hospitalised than women, who were older. A North-South divide was noted. Twenty seven percent of patients experienced readmission within 1 month. Trajectories of care were significantly different by sex and age. Overall in-hospital death was 3.3%, decreasing by 15% during the period. The highest adjusted mortality rates were observed for inpatients aged 80.ConclusionWe outlined the public health burden of this condition and the importance of improving the trajectories of care as an aid for better care.

Standardized mortality ratiosb'*' (SMR), given for both gender and for all causes of death in the ORICAMs cohort.

Snapshot img

Cardiovascular Therapeutics Market Size 2025-2029

The cardiovascular therapeutics market size is forecast to increase by USD 25.32 billion, at a CAGR of 4.6% between 2024 and 2029.

The market is experiencing significant growth and transformation, driven by the increasing risk factors for cardiovascular diseases and the advent of novel technologies. The rising prevalence of obesity, sedentary lifestyles, and unhealthy diets are leading to a surge in cardiovascular conditions, creating a vast demand for effective therapeutic solutions. One of the most promising developments in the market is the advent of Novel Oral Anticoagulants (NOACs), which offer improved safety and efficacy compared to traditional anticoagulants. These next-generation drugs are revolutionizing the treatment of atrial fibrillation, deep vein thrombosis, and pulmonary embolism, providing better patient outcomes and reduced healthcare costs.
Another trend shaping the market is the emergence of wearable defibrillators, which enable early detection and intervention of life-threatening cardiac arrhythmias. These portable devices offer significant advantages over conventional implantable defibrillators, including greater patient mobility and reduced invasiveness. However, challenges remain, such as ensuring user-friendliness, affordability, and effective integration with healthcare systems, which companies must address to capitalize on this market opportunity.

What will be the Size of the Cardiovascular Therapeutics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by the persistent challenge of managing complex cardiovascular conditions and addressing the ever-growing burden of cardiovascular risk factors. Antianginal drugs, including beta blockers, play a crucial role in mitigating symptoms of angina. However, the focus is shifting towards a more holistic approach, integrating family history, lifestyle modifications, and personalized medicine. Cardiac risk factors, such as physical inactivity and smoking, remain significant contributors to the disease burden. Advanced technologies, like cardiac computed tomography and genetic testing, are transforming diagnosis and treatment, enabling earlier intervention and improved patient outcomes. The drug approval process is undergoing significant changes, with an increased emphasis on clinical trials and the use of biomarkers, such as natriuretic peptides and creatine kinase, to assess drug efficacy.

Cardiovascular devices, including cardiac glycosides and drug delivery systems, are also advancing, offering new treatment options and improving patient care. Aortic aneurysm repair and cardiac rehabilitation are gaining prominence, reflecting the importance of addressing the long-term management of cardiovascular conditions. Antihypertensive drugs, including calcium channel blockers and ACE inhibitors, continue to be a mainstay in treating hypertension, while lipid-lowering agents and antihypertensive drugs remain essential in managing dyslipidemia and hypertension, respectively. Patient education and lifestyle modifications, such as weight management and smoking cessation, are increasingly recognized as critical components of effective cardiovascular care. The role of healthcare policy in shaping the market landscape and ensuring access to these advanced treatments is a continuous area of focus.

In the ever-changing landscape of cardiovascular therapeutics, ongoing research and innovation are essential to address the evolving needs of patients and healthcare providers. The market dynamics are shaped by a complex interplay of scientific advancements, regulatory requirements, and healthcare policy. The integration of technology, personalized medicine, and patient-centered care is driving the development of new treatments and improving patient outcomes.

How is this Cardiovascular Therapeutics Industry segmented?

The cardiovascular therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Distribution Channel

  Hospital pharmacy
  Retail Pharmacy
  Online pharmacy


Type

  Antithrombotic drugs
  Hypolipidemic drugs
  Others


Route Of Administration

  Oral
  Injectable
  Transdermal


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Distribution Channel Insights

The hospital pharmacy segment is estimated to witness significant growth during the forecast period.

Hospital pharmacies are a significant segment of the h

We asked French consumers about "Prevalence of health conditions" and found that "Mental health conditions (e.g., burnout, depression, anxiety)" takes the top spot, while "Physical disabilities (e.g., cerebral palsy, spinal cord injury, limb loss)" is at the other end of the ranking.These results are based on a representative online survey conducted in 2024 among 2,028 consumers in France.

Snapshot img

Longevity And Anti-Senescence Therapy Market Size 2025-2029

The longevity and anti-senescence therapy market size is forecast to increase by USD 9.43 billion at a CAGR of 5.2% between 2024 and 2029.

The market exhibit significant growth due to the increasing elderly population and advancements in research and development. Small molecules targeting DNA sequencing repair and mitochondrial functions are at the forefront of anti-senescence therapies, with clinical trials underway to assess their safety and efficacy. Strategic collaborations and partnerships between gerontology experts, biotech start-ups, and regulatory bodies are driving innovation in this field. Clinical trials are underway to evaluate their efficacy and safety. However, ethical and safety concerns surrounding hemolytic drug therapy and cell renewal therapies necessitate rigorous testing and regulatory oversight. The future of anti-senescence therapies lies in the successful integration of these advancements into regenerative medicine.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The global market for longevity and anti-senescence therapy, a branch of biotechnology reagents focused on delaying or reversing the aging process, has gained significant attention in the healthcare industry. This field targets age-related diseases, including neurodegenerative disorders, cardiovascular diseases, diabetes, osteoarthritis, cancer, and other chronic conditions. Aging is an intricate process characterized by the deterioration of organ homeostasis and the onset of various age-related diseases. The primary causes of aging are metabolic pathways, free radicals, and programmed cell death. These factors contribute to the development of chronic diseases, such as cardiovascular diseases, Parkinson's disease, and cancer.
Anti-senescence therapy aims to combat these age-related processes by employing various interventions. Calorie restriction, for instance, has shown potential in delaying aging and improving health span. Stem cell therapies offer the possibility of regeneration and repair, while targeting specific metabolic pathways can help mitigate the effects of oxidative stress and free radicals. The anti-senescence therapy market is driven by the increasing prevalence of age-related diseases and the growing demand for effective treatments. According to the World Health Organization, chronic diseases account for 71% of all deaths worldwide. As the global population ages, the need for innovative solutions to address these conditions becomes increasingly urgent.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Therapy

  Gene therapy
  Immunotherapy
  Senolytic drug therapy


Application

  Cancer
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Therapy Insights

The gene therapy segment is estimated to witness significant growth during the forecast period.

Gene therapy represents a pioneering method within the United States anti-aging and anti-senescence therapy market, focusing on the modification or correction of genes associated with aging and age-related health issues. This advanced therapy utilizes molecular techniques to directly manipulate genetic material, thereby improving cellular functions and potentially reversing or slowing down the aging process. Gene therapy holds immense potential in combating a broad spectrum of age-related conditions, including neurodegenerative diseases, cardiovascular disorders, and specific types of cancer.

Pharmacological therapies and lifestyle-related interventions are essential components of geriatric medicine. However, the emerging field of geroscience, which focuses on the biology of aging, is gaining significant traction in the anti-senescence therapy market. Molecular therapies, including gene therapy, genetic and epigenetic approaches, and cellular therapies, are at the forefront of this innovative field. Gene therapy, in particular, offers a promising solution to address the underlying causes of aging and age-related diseases. Anti-senescence therapy encompasses a range of interventions aimed at delaying or reversing the aging process. Gene therapy, with its ability to modify genes directly, represents a cutting-edge approach in this domain. By targeting genes linked to aging and age-related diseases, gene therapy holds the potential to enhance cellular functions and potentially reverse or decelerate the aging process. This therapy is particularly promising in addressing conditions such as neurodeg

In 2018, almost 3,300 people died on the French roads. Most of these people found death in an accident involving a driver under the influence of alcohol. Drunk driving is one of the main causes of fatal car accidents, not only in France but also in Europe.

The influence of speed and alcohol on car accidents

In 2016, traffic accidents were the fifth cause of death in the European Union. In France, road accidents have been considered a societal issue for decades. The French Government has implemented road safety measures in order to limit high-speed and fight against driving under influence. However, these two reasons keep being the main killers on the road, particularly among young drivers. Between 2013 and 2015, more than 45 percent of road fatalities caused by speed concerned drivers aged 18 to 24 years. Over the same time period, alcohol was the second main cause of fatal car accidents which involved young drivers.

The decrease of road accidents?

On a general level, the number of road fatalities in France seems to be decreasing. On the tolled motorway network, for example, the death rate per billion kilometers went from 4.8 in 2000 down to 1.8 in 2015. In terms of number of road traffic fatalities per 100,000 inhabitants, France is not especially well-ranked in Europe. However, it is one of the only European nations which have seen a decrease in pedestrian and cyclist fatalities from 2010 to 2016, while for the same period the decrease in road deaths reached nearly 13 percent.

In the Pays de la Loire region, 70 percent of people consider driving under the influence of alcohol to be one the main causes of fatal accidents on the roads in France. On average, 63 percent of French people deem drunk driving to be a main cause behind road deaths.